Plasma levels of macrophage migration inhibitory factor and d-dopachrome tautomerase show a highly specific profile in early life

Frontiers in Immunology

Volumn 8, Issue JAN, 2017, Pages

  Roger, Thierry ^a   Schlapbach, Luregn J ^b,c,d   Schneider, Anina ^a   Weier, Manuela ^a   Wellmann, Sven ^e   Marquis, Patrick ^a   Vermijlen, David ^f   G J Sweep, Fred C ^g   Leng, Lin ^h   Bucala, Richard ^h   Calandra, Thierry ^a   Giannoni, Eric ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h YALE UNIVERSITY   (United States)

Author keywords

Bronchopulmonary dysplasia; D dopachrome tautomerase; Fetus; Healthy adult; Innate immunity; Macrophage migration inhibitory factor; Neonate; Sepsis

Indexed keywords

DOPACHROME TAUTOMERASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD CELL; BLOOD LEVEL; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE INACTIVATION; HUMAN; INNATE IMMUNITY; LUNG DYSPLASIA; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NEWBORN; OXYGEN TENSION; PREMATURITY; UMBILICAL CORD BLOOD;

EID: 85012180611     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00026     Document Type: Article

References (67)

1. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol (2003) 3(10):791-800. doi:10.1038/nri1200
2. Bucala R, Donnelly SC. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity (2007) 26(3):281-5. doi:10.1016/j.immuni.2007.03.005
3. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum (1999) 42(8):1601-8. doi:10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B
4. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol (2004) 31(2):268-73.
5. Shimizu T, Nishihira J, Mizue Y, Nakamura H, Abe R, Watanabe H, et al. High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol (2001) 116(6):989-90. doi:10.1046/j.0022-202x.2001.01366.x
6. Shimizu T, Abe R, Ohkawara A, Mizue Y, Nishihira J. Macrophage migration inhibitory factor is an essential immunoregulatory cytokine in atopic dermatitis. Biochem Biophys Res Commun (1997) 240(1):173-8. doi:10.1006/bbrc.1997.7633
7. Murakami H, Akbar SM, Matsui H, Onji M. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest (2001) 31(4):337-43. doi:10.1046/j.1365-2362.2001.00796.x
8. Yamaguchi E, Nishihira J, Shimizu T, Takahashi T, Kitashiro N, Hizawa N, et al. Macrophage migration inhibitory factor (MIF) in bronchial asthma. Clin Exp Allergy (2000) 30(9):1244-9. doi:10.1046/j.1365-2222.2000.00888.x
9. Meyer-Siegler KL, Bellino MA, Tannenbaum M. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer (2002) 94(5):1449-56. doi:10.1002/cncr.10354
10. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med (2000) 6(2):164-70. doi:10.1038/72262
11. Lehmann LE, Novender U, Schroeder S, Pietsch T, von Spiegel T, Putensen C, et al. Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med (2001) 27(8):1412-5. doi:10.1007/s001340101022
12. Bozza FA, Gomes RN, Japiassu AM, Soares M, Castro-Faria-Neto HC, Bozza PT, et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock (2004) 22(4):309-13. doi:10.1097/01.shk.0000140305.01641.c8
13. Emonts M, Sweep FC, Grebenchtchikov N, Geurts-Moespot A, Knaup M, Chanson AL, et al. Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis (2007) 44(10):1321-8. doi:10.1086/514344
14. Renner P, Roger T, Calandra T. Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis (2005) 41(Suppl 7):S513-9. doi:10.1086/432009
15. Bucala R. MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity. J Clin Immunol (2013) 33(Suppl 1):S72-8. doi:10.1007/s10875-012-9781-1
16. Renner P, Roger T, Bochud PY, Sprong T, Sweep FC, Bochud M, et al. A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. FASEB J (2012) 26(2):907-16. doi:10.1096/fj.11-195065
17. Savva A, Brouwer MC, Roger T, Valls Seron M, Le Roy D, Ferwerda B, et al. Functional polymorphisms of macrophage migration inhibitory factor as predictors of morbidity and mortality of pneumococcal meningitis. Proc Natl Acad Sci U S A (2016) 113(13):3597-602. doi:10.1073/pnas.1520727113
18. Grieb G, Merk M, Bernhagen J, Bucala R. Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect (2010) 23(4):257-64. doi:10.1358/dnp.2010.23.4.1453629
19. Morand EF, Leech M, Bernhagen J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov (2006) 5(5):399-410. doi:10.1038/nrd2029
20. Greven D, Leng L, Bucala R. Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Targets (2010) 14(3):253-64. doi:10.1517/14728220903551304
21. Lubetsky JB, Dios A, Han J, Aljabari B, Ruzsicska B, Mitchell R, et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem (2002) 277(28):24976-82. doi:10.1074/jbc.M203220200
22. Ouertatani-Sakouhi H, El-Turk F, Fauvet B, Cho MK, Pinar Karpinar D, Le Roy D, et al. Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action. J Biol Chem (2010) 285(34):26581-98. doi:10.1074/jbc.M110.113951
23. Ouertatani-Sakouhi H, El-Turk F, Fauvet B, Roger T, Le Roy D, Karpinar DP, et al. A new class of isothiocyanate-based irreversible inhibitors of macrophage migration inhibitory factor. Biochemistry (2009) 48(41):9858-70. doi:10.1021/bi900957e
24. Kerschbaumer RJ, Rieger M, Volkel D, Le Roy D, Roger T, Garbaraviciene J, et al. Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the beta-sheet structure of MIF. J Biol Chem (2012) 287(10):7446-55. doi:10.1074/jbc.M111.329664
25. Kobayashi S, Satomura K, Levsky JM, Sreenath T, Wistow GJ, Semba I, et al. Expression pattern of macrophage migration inhibitory factor during embryogenesis. Mech Dev (1999) 84(1-2):153-6. doi:10.1016/S0925-4773(99)00057-X
26. Faria MR, Hoshida MS, Ferro EA, Ietta F, Paulesu L, Bevilacqua E. Spatiotemporal patterns of macrophage migration inhibitory factor (Mif) expression in the mouse placenta. Reprod Biol Endocrinol (2010) 8:95. doi:10.1186/1477-7827-8-95
27. Kevill KA, Bhandari V, Kettunen M, Leng L, Fan J, Mizue Y, et al. A role for macrophage migration inhibitory factor in the neonatal respiratory distress syndrome. J Immunol (2008) 180(1):601-8. doi:10.4049/jimmunol.180.1.601
28. Ietta F, Todros T, Ticconi C, Piccoli E, Zicari A, Piccione E, et al. Macrophage migration inhibitory factor in human pregnancy and labor. Am J Reprod Immunol (2002) 48(6):404-9. doi:10.1034/j.1600-0897.2002.01152.x
29. Chaiworapongsa T, Romero R, Espinoza J, Kim YM, Edwin S, Bujold E, et al. Macrophage migration inhibitory factor in patients with preterm parturition and microbial invasion of the amniotic cavity. J Matern Fetal Neonatal Med (2005) 18(6):405-16. doi:10.1080/14767050500361703
30. Prencipe G, Auriti C, Inglese R, Devito R, Ronchetti MP, Seganti G, et al. A polymorphism in the macrophage migration inhibitory factor promoter is associated with bronchopulmonary dysplasia. Pediatr Res (2011) 69(2):142-7. doi:10.1203/PDR.0b013e3182042496
31. Thomas W, Seidenspinner S, Kawczynska-Leda N, Kramer BW, Chmielnicka-Kopaczyk M, Marx A, et al. Systemic fetal inflammation and reduced concentrations of macrophage migration inhibitory factor in tracheobronchial aspirate fluid of extremely premature infants. Am J Obstet Gynecol (2008) 198(1):e1-6. doi:10.1016/j.ajog.2007.06.010
32. Schlapbach LJ, Graf R, Woerner A, Fontana M, Zimmermann-Baer U, Glauser D, et al. Pancreatic stone protein as a novel marker for neonatal sepsis. Intensive Care Med (2013) 39(4):754-63. doi:10.1007/s00134-012-2798-3
33. Roger T, Schneider A, Weier M, Sweep FC, Le Roy D, Bernhagen J, et al. High expression levels of macrophage migration inhibitory factor sustain the innate immune responses of neonates. Proc Natl Acad Sci U S A (2016) 113(8):E997-1005. doi:10.1073/pnas.1514018113
34. Merk M, Mitchell RA, Endres S, Bucala R. d-dopachrome tautomerase (d-DT or MIF-2): doubling the MIF cytokine family. Cytokine (2012) 59(1):10-7. doi:10.1016/j.cyto.2012.03.014
35. Merk M, Zierow S, Leng L, Das R, Du X, Schulte W, et al. The d-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proc Natl Acad Sci U S A (2011) 108(34):E577-85. doi:10.1073/pnas.1102941108
36. Kim BS, Stoppe C, Grieb G, Leng L, Sauler M, Assis D, et al. The clinical significance of the MIF homolog d-dopachrome tautomerase (MIF-2) and its circulating receptor (sCD74) in burn. Burns (2016) 42(6):1265-76. doi:10.1016/j.burns.2016.02.005
37. Stoppe C, Rex S, Goetzenich A, Kraemer S, Emontzpohl C, Soppert J, et al. Interaction of MIF family proteins in myocardial ischemia/reperfusion damage and their influence on clinical outcome of cardiac surgery patients. Antioxid Redox Signal (2015) 23(11):865-79. doi:10.1089/ars.2014.6243
38. Dimova T, Brouwer M, Gosselin F, Tassignon J, Leo O, Donner C, et al. Effector Vgamma9Vdelta2 T cells dominate the human fetal gammadelta T-cell repertoire. Proc Natl Acad Sci U S A (2015) 112(6):E556-65. doi:10.1073/pnas.1412058112
39. Schlapbach LJ, Giannoni E, Wellmann S, Stocker M, Ammann RA, Graf R. Normal values for pancreatic stone protein in different age groups. BMC Anesthesiol (2015) 15:168. doi:10.1186/s12871-015-0149-y
40. Grass B, Baumann P, Arlettaz R, Fouzas S, Meyer P, Spanaus K, et al. Cardiovascular biomarkers pro-atrial natriuretic peptide and pro-endothelin-1 to monitor ductus arteriosus evolution in very preterm infants. Early Hum Dev (2014) 90(6):293-8. doi:10.1016/j.earlhumdev.2014.03.002
41. Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum (2005) 52(10):3020-9. doi:10.1002/art.21285
42. Giannoni E, Guignard L, Knaup Reymond M, Perreau M, Roth-Kleiner M, Calandra T, et al. Estradiol and progesterone strongly inhibit the innate immune response of mononuclear cells in newborns. Infect Immun (2011) 79(7):2690-8. doi:10.1128/IAI.00076-11
43. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA (2015) 314(10):1039-51. doi:10.1001/jama.2015.10244
44. Pepe GJ, Albrecht ED. Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Endocr Rev (1995) 16(5):608-48. doi:10.1210/er.16.5.608
45. Pasupuleti V, Du W, Gupta Y, Yeh IJ, Montano M, Magi-Galuzzi C, et al. Dysregulated d-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis. J Biol Chem (2014) 289(6):3713-23. doi:10.1074/jbc.M113.500694
46. Baugh JA, Gantier M, Li L, Byrne A, Buckley A, Donnelly SC. Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem Biophys Res Commun (2006) 347(4):895-903. doi:10.1016/j.bbrc.2006.06.148
47. Park AM, Sanders TA, Maltepe E. Hypoxia-inducible factor (HIF) and HIF-stabilizing agents in neonatal care. Semin Fetal Neonatal Med (2010) 15(4):196-202. doi:10.1016/j.siny.2010.05.006
48. Oda S, Oda T, Nishi K, Takabuchi S, Wakamatsu T, Tanaka T, et al. Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner. PLoS One (2008) 3(5):e2215. doi:10.1371/journal.pone.0002215
49. Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, et al. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer (2003) 107(1):22-9. doi:10.1002/ijc.11287
50. Ren Y, Chan HM, Li Z, Lin C, Nicholls J, Chen CF, et al. Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. Oncogene (2004) 23(23):4146-54. doi:10.1038/sj.onc.1207490
51. Prabhu SB, Rathore DK, Nair D, Chaudhary A, Raza S, Kanodia P, et al. Comparison of human neonatal and adult blood leukocyte subset composition phenotypes. PLoS One (2016) 11(9):e0162242. doi:10.1371/journal.pone.0162242
52. Dowling DJ, Levy O. Ontogeny of early life immunity. Trends Immunol (2014) 35(7):299-310. doi:10.1016/j.it.2014.04.007
53. Schlapbach LJ, Frey S, Roger T, Calandra T, Nelle M, Aebi C, et al. Umbilical venous concentrations of estradiol in infants with early-onset neonatal sepsis and chorioamnionitis. J Neonatal Perinatal Med (2011) 4:147-54.
54. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels MR. The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol (2006) 177(3):1956-66. doi:10.4049/jimmunol.177.3.1956
55. Belderbos ME, Levy O, Stalpers F, Kimpen JL, Meyaard L, Bont L. Neonatal plasma polarizes TLR4-mediated cytokine responses towards low IL-12p70 and high IL-10 production via distinct factors. PLoS One (2012) 7(3):e33419. doi:10.1371/journal.pone.0033419
56. Kan B, Razzaghian HR, Lavoie PM. An immunological perspective on neonatal sepsis. Trends Mol Med (2016) 22(4):290-302. doi:10.1016/j.molmed.2016.02.001
57. Shane AL, Stoll BJ. Neonatal sepsis: progress towards improved outcomes. J Infect (2014) 68(Suppl 1):S24-32. doi:10.1016/j.jinf.2013.09.011
58. Giannoni E, Berger C, Stocker M, Agyeman P, Posfay-Barbe KM, Heininger U, et al. Incidence and outcome of group B streptococcal sepsis in infants in Switzerland. Pediatr Infect Dis J (2016) 35(2):222-4. doi:10.1097/INF.0000000000000974
59. Sun H, Choo-Wing R, Sureshbabu A, Fan J, Leng L, Yu S, et al. A critical regulatory role for macrophage migration inhibitory factor in hyperoxia-induced injury in the developing murine lung. PLoS One (2013) 8(4):e60560. doi:10.1371/journal.pone.0060560
60. Kobold S, Merk M, Hofer L, Peters P, Bucala R, Endres S. The macrophage migration inhibitory factor (MIF)-homologue d-dopachrome tautomerase is a therapeutic target in a murine melanoma model. Oncotarget (2014) 5(1):103-7. doi:10.18632/oncotarget.1560
61. Brock SE, Rendon BE, Xin D, Yaddanapudi K, Mitchell RA. MIF family members cooperatively inhibit p53 expression and activity. PLoS One (2014) 9(6):e99795. doi:10.1371/journal.pone.0099795
62. Rajasekaran D, Zierow S, Syed M, Bucala R, Bhandari V, Lolis EJ. Targeting distinct tautomerase sites of d-DT and MIF with a single molecule for inhibition of neutrophil lung recruitment. FASEB J (2014) 28(11):4961-71. doi:10.1096/fj.14-256636
63. Gibbons D, Fleming P, Virasami A, Michel ML, Sebire NJ, Costeloe K, et al. Interleukin-8 (CXCL8) production is a signatory T cell effector function of human newborn infants. Nat Med (2014) 20(10):1206-10. doi:10.1038/nm.3670
64. Lue H, Dewor M, Leng L, Bucala R, Bernhagen J. Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell Signal (2011) 23(1):135-44. doi:10.1016/j.cellsig.2010.08.013
65. Yende S, Angus DC, Kong L, Kellum JA, Weissfeld L, Ferrell R, et al. The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. FASEB J (2009) 23(8):2403-11. doi:10.1096/fj.09-129445
66. Awandare GA, Martinson JJ, Were T, Ouma C, Davenport GC, Ong'echa JM, et al. MIF (macrophage migration inhibitory factor) promoter polymorphisms and susceptibility to severe malarial anemia. J Infect Dis (2009) 200(4):629-37. doi:10.1086/600894
67. Asgari S, McLaren PJ, Peake J, Wong M, Wong R, Bartha I, et al. Exome sequencing reveals primary immunodeficiencies in children with community-acquired Pseudomonas aeruginosa sepsis. Front Immunol (2016) 7:357. doi:10.3389/fimmu.2016.00357